4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript
4D Molecular Therapeutics, Inc. ( FDMT ) Jefferies London Healthcare Conference 2025 November 18, 2025 4:00 AM EST Company Participants David Kirn - Co-Founder, CEO & Director Christopher Simms - Chief Commercial Officer Presentation Operator Good morning, and welcome to the Jefferies 2025 Healthcare Conference. It's my pleasure now to introduce David Kirn, CEO; and Chris Simms, Chief Commercial Officer of 4D Molecular Therapeutics.
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to a loss of $0.79 per share a year ago.
Wall Street Analysts See a 208.52% Upside in 4D Molecular Therapeutics (FDMT): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 208.5% in 4D Molecular Therapeutics (FDMT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors
4D Molecular Therapeutics trades below its cash balance, offering significant upside as its late-stage gene therapy programs advance. FDMT's lead asset, 4D-150, targets wet AMD and DME, with Phase 3 data expected in early 2027 and regulatory designations accelerating its path. The pipeline includes diversified assets like 4D-710 for cystic fibrosis, reducing reliance on a single program and enhancing long-term growth potential.
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.63 per share a year ago.
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.66 per share a year ago.
4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression
4D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential to disrupt the anti-VEGF treatment paradigm for retinal diseases. The company has a strong cash position of $551 million, funding operations through 2027, allowing it to avoid immediate financing needs. 4D-150's Phase 2 data shows reduced need for supplemental injections, positioning it as a long-term, durable treatment for wet AMD and DME.
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.24 per share a year ago.
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Encourages Investor Participation
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholders Are Encouraged To Join The Schall Law Firm In An Inquiry Into 4D Molecular Therapeutics, Inc. For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D Molecular Therapeutics" or "the Company") (NASDAQ:FDMT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
